Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rasagiline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 8/20 | 0.79 |
| ▸ | ACHE | P22303 | 12/20 | 0.79 |
| ▸ | MAOA | P21397 | 7/20 | 0.79 |
| ▸ | BCHE | P06276 | 2/20 | 0.79 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.79 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.79 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.79 |
| ▸ | HTR6 | P50406 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rasagiline SCHEMBL1818820 | 0.95 | ACHE (0.75) | ACHEMAOBMAOABCHEADRA2B | |
| Rasagiline SCHEMBL6120649 | 0.92 | ACHE (0.79) | ACHEMAOBMAOABCHEADRA2B | |
| Rasagiline SCHEMBL933178 | 0.92 | ACHE (0.79) | ACHEMAOBMAOABCHEADRA2B | |
| Rasagiline SCHEMBL932650 | 0.92 | ACHE (0.83) | ACHEMAOBMAOABCHEADRA2B | |
| Rasagiline SCHEMBL1972002 | 0.92 | ACHE (0.83) | ACHEMAOBMAOABCHEADRA2B | |
| Rasagiline SCHEMBL828682 | 0.92 | ACHE (0.83) | ACHEMAOBMAOABCHEADRA2B | |
| Rasagiline SCHEMBL933130 | 0.92 | ACHE (0.70) | ACHEMAOBMAOABCHEADRA2B | |
| Rasagiline SCHEMBL932880 | 0.91 | ACHE (0.68) | ACHEMAOBMAOABCHEADRA2B | |
| Palmitic Acid SCHEMBL2028967 | 0.90 | ACHE (0.67) | ACHEMAOBMAOABCHEADRA2B | |
| Rasagiline SCHEMBL933851 | 0.90 | ACHE (0.67) | ACHEMAOBMAOABCHEADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041920-A1 | NEW SALT FORMS OF AN AMINOINDAN DERIVATIVE | MEDICHEM, S.A. (ES) | 2010-02-18 | — | — | US | claimed |
| WO-2010007181-A2 | NEW SALT FORMS OF AN AMINOINDAN DERIVATIVE | MEDICHEM, S.A. (ES) | 2010-01-21 | — | — | WO | claimed |
| EP-3079672-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A PHARMACEUTICALLY ACCEPTABLE SALT OF RASAGILINE | KRKA D D NOVO MESTO (SI) | 2020-05-13 | — | — | EP | disclosed |
| EP-3079672-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PHARMACEUTICALLY ACCEPTABLE SALT OF RASAGILINE | KRKA, d.d., Novo mesto (SI) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015086768-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PHARMACEUTICALLY ACCEPTABLE SALT OF RASAGILINE | KRKA, D.D., NOVO MESTO (SI) | 2015-06-18 | — | — | WO | disclosed |
| WO-2013182625-A1 | PHARMACEUTICAL FORMULATION WITH PROPARGYLAMINE COMPOUND | ACTAVIS GROUP PTC EHF (IS) | 2013-12-12 | — | — | WO | disclosed |
| EP-2519496-A2 | SOLID STATE FORMS OF RASAGILINE SALTS | Actavis Group Ptc Ehf (IS) | 2012-11-07 | — | — | EP | disclosed |
| US-20120269871-A1 | SOLID STATE FORMS OF RASAGILINE SALTS | ACTAVIS GROUP PTC EHF (IS) | 2012-10-25 | — | — | US | disclosed |
| WO-2011080589-A2 | SOLID STATE FORMS OF RASAGILINE SALTS | ACTAVIS GROUP PTC EHF (IS) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011064216-A1 | NOVEL SALTS OF RASAGILINE | LEK PHARMACEUTICALS D.D. (SI) | 2011-06-03 | — | — | WO | disclosed |
| EP-2325159-A1 | Novel salts of rasagiline | LEK Pharmaceuticals d.d. (SI) | 2011-05-25 | — | — | EP | disclosed |
| US-20100041920-A1 | NEW SALT FORMS OF AN AMINOINDAN DERIVATIVE | MEDICHEM, S.A. (ES) | 2010-02-18 | — | — | US | disclosed |
| WO-2010007181-A2 | NEW SALT FORMS OF AN AMINOINDAN DERIVATIVE | MEDICHEM, S.A. (ES) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120269871-A1 | SOLID STATE FORMS OF RASAGILINE SALTS | RAB7A, RAB27A, RAB29 | MAOB 1819/4885ACHE 648/4885MAOA 1865/4885 |
| US-20100041920-A1 | NEW SALT FORMS OF AN AMINOINDAN DERIVATIVE | RAB35, RAB7A, RAB10 | MAOB 2254/4885ACHE 1630/4885MAOA 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.